COMMUNIQUÉS West-GlobeNewswire

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT [...]
Ajax Therapeutics Announces Oral Presentation of Clinical Results from AJX-101, a Phase I study of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the European Hematology Society (EHA) 2026 Congress
12/05/2026
– Company unveils first proof-of concept clinical data of AJ1-11095 in patients with myelofibrosis who have been previously treated with a type I JAK2 Inhibitor – NEW YORK and CAMBRIDGE, Mass., May 12, 2026 (GLOBE [...]
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
12/05/2026
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June [...]
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell [...]
Cellectis présentera des données cliniques sur lasmé-cel et éti-cel au congrès annuel de l’EHA 2026
12/05/2026
NEW YORK, 12 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
12/05/2026
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline [...]
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
12/05/2026
Data will reflect the functional characterization of EVX-04 Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing [...]
PayZen Report: Healthcare Financial Pressures Mount as 73% of Systems Elevate Patient Payment Balances to a Top Priority
12/05/2026
PayZen’s State of Healthcare Affordability: The Provider Perspective 2026 report highlights rising focus on better financial experiences, limited payment flexibility, and AI acceleration SAN FRANCISCO, May 12, 2026 ( [...]
Four Winners Selected in PerfectServe’s 2026 Nurses of Note Awards Program
12/05/2026
Winners are nurse leaders whose work focuses on mentorship for new nurses, neonatal care and education, and better perioperative care team communication MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- PerfectServe®, a leading [...]
Ontra Launches AI-Powered DDQ Solution to Accelerate Investor Diligence for Private Markets Firms
12/05/2026
Co-developed with leading private markets firms, Ontra’s solution delivers the speed, accuracy, and consistency investor diligence demands SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- Ontra , the leader in AI-powered [...]
Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026
12/05/2026
RTX001 is an engineered Regenerative Macrophage Therapy for end-stage liver disease (ESLD) with anti-inflammatory and anti-fibrotic properties These new preclinical data demonstrate RTX001’s pharmacology, safety, [...]
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 [...]
LiveWorld Reports First Quarter 2026 Financial Results
12/05/2026
LiveWorld continues to increase its AI investment CAMPBELL, Calif. and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for first quarter 2026. Three [...]
PrognomiQ Announces Breakthrough Results for the Early Detection of Lung Cancer in Ongoing Real-World Study for Its Novel Blood Test
12/05/2026
ProVue Lung blood test detects lung cancers with 89% overall sensitivity and 83% sensitivity at stage I, the earliest and most treatable stage SAN MATEO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- PrognomiQ , a healthcare [...]
JenaValve Appoints Dave Haan as Vice President of Clinical Affairs
12/05/2026
IRVINE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy ® Transcatheter Heart Valve (THV) System, today announced the appointment of Dave Haan as Vice [...]
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
12/05/2026
Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research
12/05/2026
Grant program expands access to advanced single-domain antibody technologies to support the research and development of next-generation therapies BOSTON and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Fortis Life Sciences [...]
ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
12/05/2026
ENvue™ Navigation Platform adopted as the standard of care for bedside feeding tube placement across the integrated health network TYLER, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc . (NASDAQ: FEED) (“ [...]

Pages